Caterpillar overpays for Humira.
We can prove it.
The transparent specialty infusion benefit playbook for Cat HR & Benefits — drops your drug spend 60% across Humira, Remicade, Stelara, and Entyvio without disrupting carriers or networks.
JetBlue. Stop overpaying
for Remicade.
The transparent specialty infusion benefit for employee-experience-forward airlines — drops drug costs 60% and earns a 92 NPS from your crew across every hub from JFK to Boston to Fort Lauderdale.
Manufacturers, stop
overpaying for infusions.
Cooper Farms, Moog, and Internova cut their specialty drug costs 60% with Leap. The transparent specialty infusion benefit built for self-funded manufacturers — workforce demographics drive specialty drug spend, and Leap drops it without disrupting carriers.
The infusion benefit
your clients are missing.
Leap drops your clients' specialty drug costs 60% — and brings your book of business a real differentiator. Channel-friendly economics. White-glove patient care. The play your clients haven't seen.
